作者回复。
Authors' Reply.
机构信息
INSERM U1245 Team 03, Centre Henri Becquerel, Rouen.
INSERM U1245 Team 03, Centre Henri Becquerel, Rouen.
出版信息
J Mol Diagn. 2018 Mar;20(2):266. doi: 10.1016/j.jmoldx.2017.12.001.
PMID:29482771
Abstract
Authors' Reply to the Letter to the Editor by Y. Lynn Wang (MYD88 mutations and sensitivity to ibrutinib therapy).
摘要
作者对 Wang Y. Lynn（MYD88 突变与伊布替尼治疗敏感性）的来信的回复
相似文献
1
Authors' Reply.作者回复。
J Mol Diagn. 2018 Mar;20(2):266. doi: 10.1016/j.jmoldx.2017.12.001.
2
MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia.MYD88突变与华氏巨球蛋白血症患者对伊布替尼的反应
N Engl J Med. 2015 Aug 6;373(6):584-6. doi: 10.1056/NEJMc1506192.
3
MYD88 Mutations and Sensitivity to Ibrutinib Therapy.MYD88 突变与伊布替尼治疗敏感性。
J Mol Diagn. 2018 Mar;20(2):264-266. doi: 10.1016/j.jmoldx.2017.11.006.
4
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.帕比司他与伊布替尼在 MYD88 L265P 突变的弥漫性大 B 细胞淋巴瘤细胞中具有协同作用。
JCI Insight. 2017 Mar 23;2(6):e90196. doi: 10.1172/jci.insight.90196.
5
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.TP53 突变与突变型 MYD88 和 CXCR4 相关，并赋予瓦尔登斯特伦巨球蛋白血症不良预后。
Br J Haematol. 2019 Jan;184(2):242-245. doi: 10.1111/bjh.15560. Epub 2018 Sep 5.
6
Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation.携带MYD88 L265P基因突变的IgG淋巴浆细胞淋巴瘤患者对伊布替尼的反应。
Leuk Lymphoma. 2016 Nov;57(11):2699-701. doi: 10.3109/10428194.2016.1157875. Epub 2016 Mar 16.
7
CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.CXCR4 无义突变和移码突变促进伊布替尼耐药，但不能取代 MYD88(L265P)在华氏巨球蛋白血症细胞中的生存信号传导。
Br J Haematol. 2015 Mar;168(5):701-7. doi: 10.1111/bjh.13200. Epub 2014 Nov 5.
8
clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia.克隆性是影响华氏巨球蛋白血症患者伊布替尼治疗效果的重要决定因素。
Blood Adv. 2019 Oct 8;3(19):2800-2803. doi: 10.1182/bloodadvances.2019000635.
9
A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.一项头对头的 III 期研究比较了zanubrutinib 与 ibrutinib 在华氏巨球蛋白血症患者中的疗效。
Future Oncol. 2018 Sep;14(22):2229-2237. doi: 10.2217/fon-2018-0163. Epub 2018 Jun 5.
10
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.伊布替尼单药治疗有症状、初治的华氏巨球蛋白血症患者。
J Clin Oncol. 2018 Sep 20;36(27):2755-2761. doi: 10.1200/JCO.2018.78.6426. Epub 2018 Jul 25.
Zotero 插件